JP2009504803A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504803A5
JP2009504803A5 JP2008528017A JP2008528017A JP2009504803A5 JP 2009504803 A5 JP2009504803 A5 JP 2009504803A5 JP 2008528017 A JP2008528017 A JP 2008528017A JP 2008528017 A JP2008528017 A JP 2008528017A JP 2009504803 A5 JP2009504803 A5 JP 2009504803A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
compound
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008528017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504803A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/032371 external-priority patent/WO2007024707A2/en
Publication of JP2009504803A publication Critical patent/JP2009504803A/ja
Publication of JP2009504803A5 publication Critical patent/JP2009504803A5/ja
Pending legal-status Critical Current

Links

Images

JP2008528017A 2005-08-22 2006-08-21 Ｔｌｒアゴニスト Pending JP2009504803A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71033705P 2005-08-22 2005-08-22
PCT/US2006/032371 WO2007024707A2 (en) 2005-08-22 2006-08-21 Tlr agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012254043A Division JP2013040209A (ja) 2005-08-22 2012-11-20 Ｔｌｒアゴニスト

Publications (2)

Publication Number Publication Date
JP2009504803A JP2009504803A (ja) 2009-02-05
JP2009504803A5 true JP2009504803A5 (enExample) 2009-10-01

Family

ID=37772216

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008528017A Pending JP2009504803A (ja) 2005-08-22 2006-08-21 Ｔｌｒアゴニスト
JP2012254043A Pending JP2013040209A (ja) 2005-08-22 2012-11-20 Ｔｌｒアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012254043A Pending JP2013040209A (ja) 2005-08-22 2012-11-20 Ｔｌｒアゴニスト

Country Status (7)

Country Link
US (2) US20090324551A1 (enExample)
EP (1) EP1931352B1 (enExample)
JP (2) JP2009504803A (enExample)
CN (1) CN101304748A (enExample)
CA (1) CA2620182A1 (enExample)
ES (1) ES2577514T3 (enExample)
WO (1) WO2007024707A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497765A1 (en) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
BRPI0509258A8 (pt) 2004-03-26 2019-01-22 Astrazeneca Ab composto de 8-oxoadenina 9-substituída
CA2620182A1 (en) 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
EP1939202A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
JP2009542645A (ja) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
JP2010519186A (ja) * 2007-02-19 2010-06-03 スミスクライン ビーチャム コーポレーション 免疫調節物質としてのプリン誘導体
EP2132209B8 (en) * 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
JP5329444B2 (ja) * 2007-03-19 2013-10-30 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
BRPI0811125A2 (pt) * 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolinas com propriedades imunomoduladoras
EP2170888B1 (en) * 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
US20110054168A1 (en) * 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
US8865896B2 (en) * 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
WO2009099650A2 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
BR112012009329A2 (pt) 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
JP2013512859A (ja) * 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
WO2011134669A1 (en) * 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
EP2563404B1 (en) * 2010-04-30 2016-09-21 Urogen Pharma Ltd. Phospholipid drug analogs
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
CN103370317B (zh) 2010-12-16 2015-10-07 阿斯利康(瑞典)有限公司 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
WO2012080730A1 (en) 2010-12-17 2012-06-21 Astrazeneca Ab Purine derivatives
WO2012122396A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
RU2014103159A (ru) * 2011-07-22 2015-08-27 Павел КАЛИНСКИЙ Опухолесективная модуляция хемокинов
WO2013014052A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
US9173872B2 (en) 2012-08-24 2015-11-03 Glaxosmithkline Llc Pyrazolopyrimidine compounds
WO2014052828A1 (en) 2012-09-27 2014-04-03 The Regents Of The University Of California Compositions and methods for modulating tlr4
SMT201700378T1 (it) 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
JP6216387B2 (ja) 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物
EP2958889B1 (en) 2013-02-25 2017-03-22 The Scripps Research Institute Neoseptins: small molecule adjuvants
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
ES2944541T3 (es) 2014-08-06 2023-06-22 Scripps Research Inst Adyuvantes de molécula pequeña independientes de TLR
CN112898308B (zh) * 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
KR102112192B1 (ko) 2015-11-05 2020-05-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Tlr7 효능제로서의 7-(티아졸-5-일)피롤로피리미딘 화합물
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112108A1 (en) 2016-12-13 2018-06-21 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
PL3609540T3 (pl) 2017-04-14 2023-03-27 Bolt Biotherapeutics, Inc. Sposób syntezy immunokoniugatu
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
WO2019196918A1 (zh) * 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
US20210154316A1 (en) 2018-05-17 2021-05-27 Bolt Biotherapeutics, Inc. Immunoconjugates
CN109608462B (zh) * 2018-12-15 2021-11-23 华南理工大学 一种7-烃基-9-烷氧/硫基嘌呤-8-酮类化合物及其合成方法与在药物中的应用
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
WO2021046347A1 (en) 2019-09-04 2021-03-11 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
EP4175640A1 (en) 2020-07-02 2023-05-10 VIIV Healthcare Company Method of achieving hiv viral remission using long-acting antiretroviral agents
EP4219504A4 (en) * 2020-09-27 2024-10-16 Shanghai Visonpharma Co., Ltd. MACROCYCLIC TLR7 AGONIST, MANUFACTURING METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4232094A1 (en) 2020-10-21 2023-08-30 Univerza V Ljubljani Conjugated tlr7 and nod2 agonists
CN115819215B (zh) * 2022-11-08 2024-09-13 广东省科学院化工研究所 一种路易斯酸催化合成羧酸衍生物的方法
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2025093657A1 (en) 2023-10-31 2025-05-08 Univerza V Ljubljani Conjugated tlr7 and tlr4 agonists
WO2025206344A1 (ja) * 2024-03-28 2025-10-02 日産化学株式会社 グラフェンリンカー化合物及び電界効果トランジスタバイオセンサー

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
DK0553202T3 (da) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE19637209B4 (de) * 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
DE69735292T2 (de) 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
JP4391592B2 (ja) 1996-10-25 2009-12-24 スリーエム カンパニー Ｔｈ２介在性および関連疾患治療のための免疫応答修飾化合物
JPH10298181A (ja) 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
DE69824632T2 (de) * 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
JP4375901B2 (ja) * 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
PL349773A1 (en) * 1999-01-08 2002-09-09 3M Innovative Properties Co Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2001044260A2 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
ATE345349T1 (de) 1999-12-17 2006-12-15 Ariad Pharma Inc Purinderivate
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
US20040023211A1 (en) * 2000-09-15 2004-02-05 Kees Groen System and method for optimizing drug theraphy for the treatment of diseases
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
WO2002081443A1 (en) * 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
EP3231445A1 (en) 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
ATE307132T1 (de) 2001-06-29 2005-11-15 Cv Therapeutics Inc Purin derivate als a2b adenosin rezeptor antagonisten
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
GB0206461D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
WO2004032829A2 (en) * 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
CA2497765A1 (en) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) * 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
JP2005089334A (ja) * 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
BRPI0509258A8 (pt) 2004-03-26 2019-01-22 Astrazeneca Ab composto de 8-oxoadenina 9-substituída
WO2005092892A1 (ja) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ８−オキソアデニン化合物
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US8105632B2 (en) 2004-12-07 2012-01-31 University Of Miami Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
BRPI0609399A2 (pt) 2005-03-21 2010-03-30 Ferrer Int método para produzir compostos da 1h-imidazo[4,5-c]quinolin-4-amina 1-substituìda e intermediários dos mesmos
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CA2620182A1 (en) 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
WO2007038720A2 (en) 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US8338593B2 (en) * 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
JP2011500716A (ja) 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド Ａ３アデノシン受容体アンタゴニスト
WO2009099650A2 (en) 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
BR112012009329A2 (pt) 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
EP2563366A4 (en) 2010-04-30 2013-11-20 Univ California USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS
EP2563404B1 (en) 2010-04-30 2016-09-21 Urogen Pharma Ltd. Phospholipid drug analogs
WO2011134669A1 (en) 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators

Similar Documents

Publication Publication Date Title
Reesink et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients
Phillips et al. Novel therapeutic strategies for chronic hepatitis B
JP2015504650A5 (enExample)
KR102037162B1 (ko) 바이러스병, 암 및 세포내 감염으로 인한 질병의 예방 및 치료를 위한 티아졸리드 화합물의 용도
Padalko et al. The interferon inducer ampligen [poly (I)-poly (C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis
JP2013514359A5 (enExample)
Le Grice Targeting the HIV RNA genome: high-hanging fruit only needs a longer ladder
IL296483A (en) Oligonucleotides to reduce pd–l1 expression
JP2012504632A5 (enExample)
JP2014504643A5 (enExample)
EP3139954A1 (en) Methods and compositions for treating hepatitis b virus infections
JP2016503800A5 (enExample)
RU2010112408A (ru) Фосфадиазиновые ингибиторы iv полимеразы hcv
JP2011511841A5 (enExample)
RU2011142651A (ru) Способы улучшения фармакокинетики
Guillot et al. Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes
Caviglia et al. Treatment of hepatitis D: an unmet medical need
US20140314816A1 (en) Stabilized stat3 decoy oligonucleotides and uses therefore
Soler et al. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment
Tran et al. The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 1
Bradfute The discovery and development of novel treatment strategies for filoviruses
JPH05507481A (ja) ウイルス性肝炎の診断及び治療
KR20160030099A (ko) 세포내 감염의 치료 방법
Lou et al. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery
Creighton et al. The intestinal interferon system and specialized enterocytes as putative drivers of HIV latency